Prognostic value of p53 gene mutations and the product expression in de novo acute myeloid leukemia

European Journal of Haematology

Volumn 65, Issue 1, 2000, Pages 23-31

  Nakano, Yasuyuki ^{a,b,c,d,e,f,g,h,i,j,k}   Naoe, Tomoki ^{a,b,c,d,e,f,g,h,i,j,k}   Kiyoi, Hitoshi ^{a,b,c,d,e,f,g,h,i,j,k}   Kitamura, Kunio ^{a,b,c,d,e,f,g,h,i,j,k}   Minami, Saburo ^{a,b,c,d,e,f,g,h,i,j,k}   Miyawaki, Shuichi ^{a,b,c,d,e,f,g,h,i,j,k}   Asou, Norio ^{a,b,c,d,e,f,g,h,i,j,k}   Kuriyama, Kazutaka ^{a,b,c,d,e,f,g,h,i,j,k}   Kusumoto, Shuya ^{a,b,c,d,e,f,g,h,i,j,k}   Shimazaki, Chihiro ^{a,b,c,d,e,f,g,h,i,j,k}   Akiyama, Hideki ^{a,b,c,d,e,f,g,h,i,j,k}   Saito, Kenji ^{a,b,c,d,e,f,g,h,i,j,k}   Nishimura, Miki ^{a,b,c,d,e,f,g,h,i,j,k}   Motoji, Toshiko ^{a,b,c,d,e,f,g,h,i,j,k}   Shinagawa, Katsuji ^{a,b,c,d,e,f,g,h,i,j,k}   Saito, Hidehiko ^{a,b,c,d,e,f,g,h,i,j,k}   Ohno, Ryuzo ^{a,b,c,d,e,f,g,h,i,j,k}  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Japan Red Cross Nagoya First H ^*  (Japan)

^c SAISEIKAI MAEBASHI HOSPITAL   (Japan)

^d KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^e NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^g TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^h DOKKYO MEDICAL UNIVERSITY   (Japan)

ⁱ CHIBA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^k HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Acute myeloid leukemia; p53; Prognosis

Indexed keywords

PROTEIN P53;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MISSENSE MUTATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

6-MERCAPTOPURINE; ACUTE DISEASE; ADULT; AGED; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYTARABINE; DAUNORUBICIN; DNA MUTATIONAL ANALYSIS; ETOPOSIDE; FEMALE; GENE DELETION; GENES, P53; HUMANS; JAPAN; LEUKEMIA, MYELOID; LIFE TABLES; MALE; MIDDLE AGED; MUTATION; MUTATION, MISSENSE; NEOPLASM PROTEINS; PREDNISOLONE; PROGNOSIS; REGULATORY SEQUENCES, NUCLEIC ACID; SINGLE-BLIND METHOD; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; VINCRISTINE;

EID: 0033934763     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0609.2000.90138.x     Document Type: Article

References (39)

1. 1. HARRIS CC, HOLLSTEIN M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318.
2. 2. LEVINE AJ, MOMAND J, FINLAY CA. The p53 tumour suppressor gene. Nature 1991;351:453.
3. 3. KIRSCH DG, KASTAN MB. Tumor-suppressor p53: implications for tumor development and prognosis. J Clin Oncol 1998;16:3158.
4. 4. GIACCIA AJ, KASTAN MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev 1998;12:2973.
5. 5. PREUDHOMME C, FENAUX P. The clinical significance of mutations of the P53 tumour suppressor gene in haematological malignancies. Br J Haematol 1997;98:502.
6. 6. PENAUX P, JONVEAUX P, QUIQUANDON I, et al. P53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood 1991;78:1652.
7. 7. PENAUX P, PREUDHOMME C, QUIQUANDON I, et al. Mutations of the P53 gene in acute myeloid leukaemia. Br J Haematol 1992;80:178.
8. 8. Hu G, ZHANG W, DEISSEROTH AB. P53 gene mutations in acute myelogenous leukaemia. Br J Haematol 1992;81:489.
9. 9. ZHANG W, Hu G, ESTEY E, HESTER J, DEISSEROTH A. Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-stimulated normal blood cells. Oncogene 1992; 7:1645.
10. 10. TRECCA D, LONGO L, BIONDI A, et al. Analysis of p53 gene mutations in acute myeloid leukemia. Am J Hematol 1994; 46:304.
11. 11. WATTEL E, PREUDHOMME C, HECQUET B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994;84:3148.
12. 12. AHUJA H, BAR-ELI M, ARLIN Z, et al. The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. J Clin Invest 1991:87:2042.
13. 13. NEUBAUER A, HE M, SCHMIDT CA, HUHN D, LIU ET. Genetic alterations in the p53 gene in the blast crisis of chronic myelogenous leukemia: analysis by polymerase chain reaction based techniques. Leukemia 1993;7:593.
14. 14. CORDONE I, MASI S, MAURO FR, et al. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood 1998;91:4342.
15. 15. ICHIKAWA A, KINOSHITA T, WATANABE T, et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997;337:529.
16. 16. BODNER SM, MINNA JD, JENSEN SM, et al. Expression of mutant p53 proteins in lung cancer correlates with the class of p53 gene mutation. Oncogene 1992;7:743.
17. 17. CASEY G, LOPEZ ME, RAMOS JC, et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. Oncogene 1996;13:1971.
18. 18. IGGO R, GATTER K, BARTEK J, LANE D, HARRIS AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990;335:675.
19. 19. GANNON JV, GREAVES R, IGGO R, LANE DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990;9:1595.
20. 20. LEPELLEY P, PREUDHOMME C, VANRUMBEKE M, QUESNEL B, COSSON A, FENAUX P. Detection of p53 mutations in hematological malignancies: comparison between immunocytochemistry and DNA analysis. Leukemia 1994;8:1342.
21. 21. NISHIO M, KOSHIKAWA T, KUROISHI T, et al. Prognostic significance of abnormal p53 accumulation in primary, resected non-small-cell lung cancers. J Clin Oncol 1996; 14:497.
22. 22. MINETA H, BORG A, DICTOR M, WAHLBERG P, AKERVALL J, WENNERBERG J. p53 mutation, but not p53 overexpression, correlates with survival in head and neck squamous cell carcinoma. Br J Cancer 1998;78:1084.
23. 23. PRIVES C. Signaling to p53: breaking the MDM2-p53 circuit. Cell 1998;95:5.
24. 24. FREEDMAN DA, LEVINE AJ. Regulation of the p53 protein by the MDM2 oncoprotein: thirty-eighth G.H.A. Clowes Memorial Award Lecture. Cancer Res 1999;59:1.
25. 25. OHNO R, KOBAYASHI T, TANIMOTO M, et al. Randomized study of individualized induction therapy with or without vincristine, and of maintenance-intensification therapy between 4 or 12 courses in adult acute myeloid leukemia. AML-87 Study of the Japan Adult Leukemia Study Group. Cancer 1993;71:3888.
26. 26. KOBAYASHI T, MIYAWAKI S, TANIMOTO M, et al. Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group. J Clin Oncol 1996;14:204.
27. 27. MIYAWAKI S, TANIMOTO M, KOBAYASHI T, et al. Randomized study of individualized induction therapy with or without etoposide in adult acute myeloid leukemia (excert for M3) (JALSG-AML92 study) and analysis of prognostic factors. Blood 1997;90:503 (abstr, suppl 1).
28. 28. DASTUGUE N, PAYEN C, LAFAGE-POCHITALOFF M, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT group. Leukemia 1995;9:1491.
29. 29. NAKANO Y, KIYOI H, MIYAWAKI S, et al. Molecular evolution of acute myeloid leukaemia in relapse: unstable N-Ras and FLT3 genes compared with p53 gene. Br J Haematol 1999;104:659.
30. 30. ORITA M, IWAHANA H, KANAZAWA H, HAYASHI K, SEKIYA T. Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. Proc Natl Acad Sci USA 1989;86:2766.
31. 31. CHOWDARY DR, DERMODY JJ, JHA KK, OZER HL. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol 1994;14.
32. 32. MAKI CG, HUIBREGTSE JM, HOWLEY PM. In vivo ubiquitination and proteasome-mediated degradation of p53 (I). Cancer Res 1996;56:2649.
33. 33. MOMAND J, ZAMBETTI GP, OLSON DC, GEORGE D, LEVINE AJ. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992;69:1237.
34. 34. BLAGOSKLONNY MV. Loss of function and p53 protein stabilization. Oncogene 1997;15:1889.
35. 35. WHITESELL L, SUTPHIN PD, PULCINI EJ, MARTINEZ JD, COOK PH. The physical association of multiple molecular chaperone proteins with mutant p53 is altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol 1998;18:1517.
36. 36. RUBIO MP, VON DEIMLING A, YANDELL DW, WIESTLER OD, GUSELLA JF, LOUIS DN. Accumulation of wild type p53 protein in human astrocytomas. Cancer Res 1993;53:3465.
37. 37. CARBONE DP, MITSUDOMI T, CHIBA I, et al. p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871. Chest 1994;106:377.
38. 38. SUTCLIFFE T, FU L, ABRAHAM J, VAZIRI H, BENCHIMOL S. A functional wild-type p53 gene is expressed in human acute myeloid leukemia cell lines. Blood 1998;92:2977.
39. 39. EL-DEIRY WS, TOKINO T, VELCULESCU VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817.